Graft Versus Host Disease (GvHD) Treatment Market Size

Q: What is the Graft Versus Host Disease Treatment Market Size in 2023?

The market is valued at US$ 2.7 billion in 2023. Read Report

Q: What will the market size be in 2033?

The market will reach US$ 5.9 billion by 2033. Read Report

Graft Versus Host Disease (GvHD) Treatment Market Outlook (2023 to 2033)

The global graft versus host disease (GvHD) treatment market size is expected to secure US$ 5,960.7 million by 2033 while expanding at a CAGR of 8.2%.

The GvHD treatment market is experiencing a steady growth in corticosteroids and combination therapies for graft-versus-host disease in HCT patients boosting the market for (GvHD) treatment. The market is likely to hold a value of US$ 2,713.6 million in 2023. From 2018 to 2022, the market displayed a growth rate of 8.2%.

Allogeneic hematopoietic cell transplant patients may benefit from recent advancements in overall survival rate and acute graft-versus-host disease (GVHD) severity levels, however, several challenges must be addressed. In addition, newer medications such as Jakafi and Rezurock have recently been approved for the prevention and treatment of chronic (GVHD) and may provide a greater benefit than older medications.

Data Points	Key Statistics
Graft Versus Host Disease (GvHD) Treatment Market Value (2023)	US$ 2,713.6 million
Graft Versus Host Disease (GvHD) Treatment Market Forecast Value (2033)	US$ 5,960.7 million
Estimated Growth Rate (2023 to 2033)	8.2% CAGR

For treating adults and pediatric patients with GVHD, Orencia (abatacept) was approved by the United States Food and Drug Administration in December 2021. In addition to treating autoimmune disorders, Orencia is also used to prevent them. T-cells are a key component of acute (GVHD), and this drug circumvents their attack by specifically binding to and modulating one of the main costimulation signals sent by these cells.

This prevents a full activation of T-cells, which prevents acute (GVHD) from occurring. Several new approaches are being evaluated by doctors to prevent (GVHD) in the future.

Approval of Orencia is expected to make stem cell transplants more accessible to a larger number of cancer patients and people with blood disorders, particularly people from diverse ethnic backgrounds. To improve treatment response, future treatments may include immunosuppression and other treatment agents, such as regenerative or tissue-repairing agents to the market.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Factors Contributing to the Market Growth

A healthy CAGR is expected to be observed for graft versus host disease treatment during the forecast period. As innovative technologies are developed, and cancer patients seek out chemotherapy treatments, the graft versus host disease (GvHD) treatment market is expected to expand from 2023 to 2033.

Cancer patients who are treated with chemotherapy are the main driving force behind the graft versus host disease (GvHD) market at present. Increasing bone marrow transplants to treat specific cancers is also fueling the global graft versus host disease market.

Human health products have become increasingly innovative and effective in recent decades. Growth in graft versus host disease (GvHD) is projected to be considerably impacted by the use of allogeneic stem cell transplants.

To stay competitive, key players focus on introducing new drugs to the market. As a result of the high investments made by the public and private sectors in research and development technology and infrastructure, it is expected that the market is expected to be provided with lucrative opportunities shortly.

A global economy that focuses on advancing technology and innovation has the potential to restore growth and ensure the future competitiveness of the pharmaceutical industry by investing in innovation and research.

Trend	The surging rate of acute GvHD, increasing rate of hematopoietic stem cell treatment, and rising number of pipeline drugs are catalyzing the demand for graft versus host disease (GvHD) treatment.
Supporting News	In October 2021, StatPearls Publishing published a report that found the incidence of acute GvHD was around 50% for patients getting HCT from matched siblings, Human Leukocyte Antigen (HLA), and unmatched donors. In June 2021, Elsevier published an article that calculates 42% of American patients are suffering from cGvHD within three years of allogeneic HCT.

Trend	Governments and industry players are heavily investing in research and development. The positive outcomes of these clinical trials are expected to result in new treatments, which are projected to propel industry growth.
Supporting News	In June 2021, Equillium Inc. stated the completion of an End-of-Phase 1 meeting with the United States FDA for itolizumab in the treatment of aGvHD patients.

Trend	Research studies to elevate the effectiveness of corticosteroids in the treatment
Supporting News	In June 2022, a clinical trial was underway. It is a multicenter, open-label, two-arm randomized trial that assesses if the addition of ruxolitinib clubbed with corticosteroids is greater than corticosteroids to treat newly diagnosed aGvHD. A 50% response rate was reported for first-line therapy.

Factors Impeding the Adoption of Graft Versus Host Disease (GvHD) Treatments

Global graft versus host disease (GvHD) market growth is likely to be hindered by costs associated with recent clinical trials and authorizations. Using steroids in the treatment of (GvHD) immune diseases, skin diseases, and other conditions may result in side effects such as glucose levels increasing, fluid retention, mood problems, appetite disorders, and stomach pain.

The use of steroids over a long period has been linked to diabetes, infection, muscle weakness, and even cancer.

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Regional Analysis

Region and their Market Share % (2022)	Countries and their Share (2022)/ Forecast CAGR %
North America had a 34.7% Share	The United States had a 30.7% Market Share
Europe had a 26.7% Share	Germany had a 3.8% Market Share The United Kingdom to register 7.3% CAGR

North America to be Driven by the Approval of Regulatory Authority for Several Medicines

As per the research, the global graft versus host disease (GvHD) treatment market is expected to be dominated by North America during the forecast period. In 2023, the region is expected to secure more than 34.7% of the total market share. As a result of a well-established medical infrastructure and the proliferation of major key players in the region, the region has become a dominant market for (GvHD) treatments.

The United States is expected to contribute the most to the development of the market during the forecast period. Growing awareness of (GVHD) has boosted the market for (GvHD) treatments in this region. New medicines are expected to propel the market growth during the forecast period. Additionally, the regulatory authority's approval for various medicines in the market also contributes to the growth of the region.

For instance, on September 22, 2021, the FDA approved Ruxolitinib for chronic graft-versus-host disease ((GVHD)) in adults and children over 12 years of age who have failed one or more lines of systemic therapy. REACH-3 (NCT03112603) evaluated Ruxolitinib's efficacy as a treatment for corticosteroid-refractory chronic (GVHD) after allogeneic stem cell transplantation compared with the best available therapy (BAT) on the market.

Use of Advanced Cancer Treatment Technologies to Fuel Europe Market

According to the analysis, the Europe GvHD treatment market is projected to be a prominent market during the forecast period. It is estimated that the region is going to hold more than 26.5% of the total market share in 2023. The growth of the market can be attributed to the rapid development of the food and beverage sector in the region.

Growing awareness, the availability of chemotherapies, and the adoption of advanced cancer treatment technologies drive the market for graft versus host disease (GvHD) treatment in these regions. In addition, the rise in the aging population, scientific advancements, and clinical trials are expected to grow the market for GvHD treatment in the market.

Category-wise Insights

Monoclonal Antibodies to Emerge as the Effective Products for Treating GvHD

According to Future Market Insights, monoclonal antibodies are expected to gain significant market share in the upcoming years. With the rapid development of pharmaceuticals and clinical trials, along with the expanding treatment for chronic diseases, the worldwide market is set for continued expansion shortly.

The increasing number of cancer cases in various regions has fuelled the growth of this GvHD treatment market in recent years. Due to their specialization in targeted cancer therapies in the medical sector, monoclonal antibodies are in high demand due to their unique properties.

Some monoclonal antibodies are also immunotherapies since they are effective in fighting cancer by turning the immune system against the disease. These treatment types are therefore growing in the market.

Acute Graft Versus Host Disease (GvHD) to Infiltrate the Global Market

The use of various treatments for GvHD is expected to drive the market and account for the greatest share in 2023. Globally, the market is expected to expand at a significant CAGR, attracting private and public investments to this market.

Ruxolitinib is becoming more widely used as an alternative treatment option for acute graft versus host disease (GvHD), which reduces the need for hospitalization unless there are complications. Increasing immunosuppression is often successfully achieved through the administration of oral or intravenous steroid medications.

The severe complications of acute graft-versus-host disease (GVHD) continue to hinder the success of allogeneic hematopoietic stem cell transplants (HSCTs). As a treatment when prophylaxis fails or remains suboptimal, the ability to prevent (GVHD) prophylaxis is crucial. The most commonly prescribed regimen for prophylaxis of (GVHD) still consists of a calcineurin inhibitor in combination with methotrexate.

Start-up Companies Playing a Crucial Role in Augmenting Sales of Graft Versus Host Disease (GvHD) Treatment

Healthcare continues to be a flourishing sector, and the demand for safe and effective graft-versus-host-disease medications is on the rise. Numerous innovative medicine solutions have been introduced in the medical field to reduce side effects and improve long-term outcomes, including the incorporation of graft versus host disease (GvHD) treatment. As start-ups realize their potential, they are firmly establishing themselves on the global market.

Some notable graft versus host disease start-up manufacturers are as follows:

Astellas Pharma was founded in 2005 as a Japanese multinational pharmaceutical company formed from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. Several drugs have been developed by the company that are used effectively to treat (GVHD) diseases and other chronic diseases.
Mesoblast Ltd, the United Kingdom-based graft versus host disease (GvHD) treatment manufacturer, offers allogeneic cellular medicines that are being developed and commercialized by Mesoblast using its proprietary technology platform to treat diseases that are resistant to conventional treatments and in which inflammation is a significant factor. Among the Company's Phases, 3 products are remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-a(GVHD)), and for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection; REVASCOR® for severe chronic heart failure; and MPC-06-ID for degenerative disc disease-related chronic low back pain.
Equillium, Inc. develops unmet medical needs in the treatment of severe autoimmune and inflammatory disorders by leveraging a deep understanding of immunobiology. The company is situated in California, United States, and was founded in 2017. A Phase 3 study is currently underway for graft-versus-host disease patients and a Phase 1b trial has been initiated for patients with lupus/lupus nephritis patients. An alopecia areata study is expected to begin enrolling patients in the second half of 2022 with EQ101, a first-in-class tri-specific cytokine inhibitor that targets IL-2, IL-9, and IL-15.

Key Segments Profiled in Market

By Product:

Monoclonal antibodies
mTOR inhibitors
Tyrosine kinase inhibitors
Thalidomide
Etanercept

By Disease:

Acute Graft Versus Host Disease (aGvHD)
Chronic Graft Versus Host Disease (cGvHD)

By Region:

North America
Latin America
Europe
Asia Pacific
Middle East & Africa

Frequently Asked Questions

What is the Graft Versus Host Disease Treatment Market Size in 2023?

The market is valued at US$ 2.7 billion in 2023.

Which are the key Market players?

Astellas Pharma, Mesoblast Ltd, and Equillium, Inc. are key market players.

What will the market size be in 2033?

The market will reach US$ 5.9 billion by 2033.

What drives the sales of Graft Versus Host Disease Treatment Market?

Increasing cases of acute GvHDwill drive the market prospects.

Which is the key segment by product?

Monoclonal antibodies segment is likely to remain preferred through 2033.

Table of Content

1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Product, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product, 2023 to 2033
5.3.1. Monoclonal antibodies Graft Versus Host Disease (GvHD) Treatment
5.3.2. mTOR inhibitors Graft Versus Host Disease (GvHD) Treatment
5.3.3. Tyrosine kinase inhibitors Graft Versus Host Disease (GvHD) Treatment
5.3.4. Thalidomide Graft Versus Host Disease (GvHD) Treatment
5.3.5. Etanercept Graft Versus Host Disease (GvHD) Treatment
5.4. Y-o-Y Growth Trend Analysis By Product, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Product, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Disease, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease, 2023 to 2033
6.3.1. Acute Graft Versus Host Disease (a(GvHD))
6.3.2. Chronic Graft Versus Host Disease (c(GvHD))
6.4. Y-o-Y Growth Trend Analysis By Disease, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Disease, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Western Europe
7.3.4. Eastern Europe
7.3.5. South Asia and Pacific
7.3.6. East Asia
7.3.7. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Product
8.2.3. By Disease
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Product
8.3.3. By Disease
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Product
9.2.3. By Disease
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Product
9.3.3. By Disease
9.4. Key Takeaways
10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. UK
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Western Europe
10.2.2. By Product
10.2.3. By Disease
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Product
10.3.3. By Disease
10.4. Key Takeaways
11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Poland
11.2.1.2. Russia
11.2.1.3. Czech Republic
11.2.1.4. Romania
11.2.1.5. Rest of Eastern Europe
11.2.2. By Product
11.2.3. By Disease
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Product
11.3.3. By Disease
11.4. Key Takeaways
12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Bangladesh
12.2.1.3. Australia
12.2.1.4. New Zealand
12.2.1.5. Rest of South Asia and Pacific
12.2.2. By Product
12.2.3. By Disease
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Product
12.3.3. By Disease
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Product
13.2.3. By Disease
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Product
13.3.3. By Disease
13.4. Key Takeaways
14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Product
14.2.3. By Disease
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Product
14.3.3. By Disease
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Product
15.1.2.2. By Disease
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Product
15.2.2.2. By Disease
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Product
15.3.2.2. By Disease
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Product
15.4.2.2. By Disease
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Product
15.5.2.2. By Disease
15.6. UK
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Product
15.6.2.2. By Disease
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Product
15.7.2.2. By Disease
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Product
15.8.2.2. By Disease
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Product
15.9.2.2. By Disease
15.10. Poland
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Product
15.10.2.2. By Disease
15.11. Russia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Product
15.11.2.2. By Disease
15.12. Czech Republic
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Product
15.12.2.2. By Disease
15.13. Romania
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Product
15.13.2.2. By Disease
15.14. India
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Product
15.14.2.2. By Disease
15.15. Bangladesh
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Product
15.15.2.2. By Disease
15.16. Australia
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Product
15.16.2.2. By Disease
15.17. New Zealand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Product
15.17.2.2. By Disease
15.18. China
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Product
15.18.2.2. By Disease
15.19. Japan
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Product
15.19.2.2. By Disease
15.20. South Korea
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Product
15.20.2.2. By Disease
15.21. GCC Countries
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Product
15.21.2.2. By Disease
15.22. South Africa
15.22.1. Pricing Analysis
15.22.2. Market Share Analysis, 2022
15.22.2.1. By Product
15.22.2.2. By Disease
15.23. Israel
15.23.1. Pricing Analysis
15.23.2. Market Share Analysis, 2022
15.23.2.1. By Product
15.23.2.2. By Disease
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Product
16.3.3. By Disease
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Sanofi
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Equillium, Inc.
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Novartis AG
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Neovii Biotech GmbH
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Merck & Co.
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Astellas Pharma Inc.
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Soligenix, Inc.
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Mesoblast Ltd
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Pfizer
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Takeda Pharmaceutical
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.11. Abbott
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology

Graft Versus Host Disease (GvHD) Treatment Market